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coworkers from Rome, Italy, showed original data on a much
debated and burning issue: is it possible to early predict response
to antiangiogenic treatment in hepatocellular carcinoma (HCC)
prior to the ﬁrst standard assessment at approximately two
months [1]?
Clearly this issue is important for any tumor. Indeed a molec-
ular characterization prior to therapy commencement has
already become part of clinical practice for some tumors, in order
to tailor the pharmacological therapy to the aim of limiting the
occurrence of non or poor responders. This is not yet in place
for HCC, where the single standard agent for advanced cases or
cases unsuitable for locoregional treatments is the antiangiogenic
drug sorafenib.
Nonetheless, even having one single agent, the question of
whether it is possible to predict the response to sorafenib before
its start is important. Unfortunately, this question has received a
negative answer so far, since no marker has been identiﬁed yet
[2] and no patient is selected for treatment based on the expec-
tations of response. The next question is, therefore, whether it
would be at least possible to have an early on-treatment informa-
tion about the outcome and most importantly about which
patient is going to rapidly progress notwithstanding sorafenib.
In fact, whoever will achieve stable disease or response will con-
tinue the systemic therapy, hence even an earlier information
about a later beneﬁcial outcome will not change the strategy,
but may only add costs. Conversely, the possibility to identify
at an early time point (within the ﬁrst 15 days after treatment
start) those patients who will subsequently show tumor
progression already at the ﬁrst imaging assessment (usually atJournal of Hepatology 20
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Open access under CC BY-NC-ND license.6–10 weeks after treatment start, corresponding to no beneﬁt
from systemic therapy) would be of crucial importance. Such
information could theoretically anticipate the stop of treatment
and accordingly could enable the enrolment in second line treat-
ment trials, before the patient’s general conditions or liver dys-
functions have deteriorated to a level no more matching the
enrolment criteria. An early stop of ineffective treatment would
also contribute to save money and avoid the persistence of possi-
ble side effects.
Clearly any such decision, to anticipatedly stop treatment, is
an important issue. Thus the tool for the decision should be spe-
ciﬁc enough to avoid false positive cases of inefﬁcacy.
The article by Zocco et al. [1] proposes the use of dynamic con-
trast enhanced ultrasound (CEUS) of tumor perfusion at two
weeks after sorafenib start as a tool to identify those patients
who will be categorized as progressors already at two months
when assessed by the mRECIST criteria, as currently recom-
mended [3,4]. The use of CEUS to this aim is not new, as it has
been studied in other tumors, and particularly in gastrointestinal
stromal tumors (GIST), treated with antiangiogenics. In this set-
ting, the use of CEUS to monitor treatment response to GIST
has been already endorsed by the European Society of Medical
Oncology [5] and was shown to provide useful information in
other tumors treated with antiangiogenics, such as renal cell car-
cinoma [6]. Some preliminary data were also reported for HCC,
but either not under the standard of treatment [7] or with very
limited number of patients [8] or using different contrast param-
eters and assessment timing [9].
CEUS is advantageous in this setting, thanks to its low cost
and easy repeatability and is very well accepted by patients.
The study by Zocco et al. [1] has some strong points. Patients
were enrolled according to the usual clinical indications to start
sorafenib, with not excessively restrictive criteria, even though
the number of patients with no extravascular spread nor macro-
vascular invasion, but only with symptomatic tumor was rela-
tively high, thus it will reﬂect the clinical practice. Only three
patients (7%) could not be included due to unsuitable ultrasound
target, thus there was not an additional reason for superselection.13 vol. 59 j 924–925
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The timing at two weeks for reassessment is reasonable. Later
time points, such as at one month, would not provide a signiﬁ-
cant advantage over standard reassessment, despite they were
used by two preliminary studies [8,9]. Conversely, earlier time
points, not investigated herein, up to a few days after treatment
start, could be of interest and deserve speciﬁc investigations. The
authors correctly separated progressors (who are the target of the
study) from non-progressors at the standard time of two months.
Very interestingly, the CEUS parameters showing most reli-
able predictive value are two variables related to the blood vol-
ume in the investigated area [10,11]. At variance, time-to-peak
which is related to blood ﬂow [10,11] was not signiﬁcantly asso-
ciated with progression, as well as mean transit time. Such data
tend to suggest that indeed CEUS is able to identify a decrease
in tumor blood volume. The fact that the former two parameters
appear to be reliable to the aim of predicting response is based on
the ﬁnding that responders showed negative values up to the
threshold of third interquartile (decrease in enhancement level)
whereas progressors had positive values. According to the results
of the study, however, progressors were considered those sub-
jects showing an increase of such values by >10% at two weeks
of treatment in comparison to baseline. Selecting higher thresh-
old would theoretically make the identiﬁcation of progressors
more speciﬁc, but would decrease the overall accuracy, as
reported by the authors, since some progressors would be consid-
ered as responders. However, in order to avoid stopping therapy
in dubious responders, a suggestion could be to initially adopt a
more conservative approach, selecting a higher threshold than
the most accurate (change >10%).
The fact that progressors were separated from non-progressor
by such a narrow range (change >10%, corresponding to slightly
more than the mean coefﬁcients of variations) justiﬁes the need
for automated and computerized calculations of signal intensity
[11], preventing the possibility to adopt a strategy only based
on visual impression. The limited coefﬁcient of variations of CEUS
quantiﬁcation and the reliability of the results may have derived
from the use of a methodology based on quantiﬁcation of pre-
compressed, raw signal data and not linearized video data [12].
This is only speculative, but just mentioning that there are differ-
ent methodologies for contrast quantiﬁcation, based on different
proprietaries softwares implies a word of caution in using the
results directly in the clinical practice, especially when the tech-
nology is not identical to the one used in this article [1]. Another
study on a more limited patient population, using a different
equipment and quantiﬁcation software, consistently showed
the Area Under the Curve of enhancement to be the most useful
parameter, which is reassuring, but the best cut-off was quite dif-
ferent [8]. Very importantly, the operators need to be adequately
trained in CEUS quantiﬁcation (which involves a speciﬁc and reli-
able choice of the scanning plane and acquisition settings and
contrast injection modality, so that subsequent scans over timeJournal of Hepatology 201could be reproduced) and the equipments or softwares should
be preliminary tested and validated.Conﬂict of interest
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